Business Context and Reporting Period
Company: Astro-Med, Inc. (Note: Input metadata referenced "Astronova," but the filing text identifies the registrant as Astro-Med, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: May 3, 2003
Business Overview: The company operates in three segments: Test & Measurement (T&M), QuickLabel Systems (QLS), and Grass-Telefactor (G-T). It manufactures and sells specialty products including test equipment, label printers, and neurophysiology systems.
Key Financial Metrics
| Metric | Q1 2003 (Ended May 3) | Q1 2002 (Ended May 4) |
|---|---|---|
| Net Sales | $13,214,120 | $11,437,728 |
| Gross Profit | $5,049,733 | $3,808,425 |
| Gross Margin | 38.2% | 33.3% |
| Operating Income | $487,380 | ($879,297) |
| Net Income | $506,059 | ($632,255) |
| Diluted EPS | $0.12 | ($0.15) |
| Cash from Operations | $783,072 | $399,269 |
| Cash & Equivalents (End of Period) | $2,828,059 | $2,725,927 |
| Total Current Liabilities | $6,716,494 | $6,129,161 |
| Long-Term Debt (Current Maturities) | $6,065 | $8,290 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% year-over-year, driven by a 30% increase in international sales (18% excluding currency effects) and a 10% increase in domestic sales.
- Profitability Turnaround: The company returned to profitability with $506,059 in net income, compared to a net loss of $632,255 in the prior year. Operating income improved from a loss of $879,297 to a profit of $487,380.
- Margin Expansion: Gross margin improved to 38.2% from 33.3%, attributed to favorable sales mix and better manufacturing overhead absorption.
- Expense Management: Selling, General, and Administrative (SG&A) expenses declined 1% due to workforce reductions implemented in the prior fiscal year. R&D expenses decreased 8% for similar reasons.
- Segment Performance:
- QLS: Sales up 14%; turned profitable with a 10.4% margin.
- G-T: Sales up 51%; margin improved to 18.5%.
- T&M: Sales declined 28% due to reduced defense spending; segment loss widened to $(383,000).
Guidance, Outlook, and Risks
Management Commentary: Management attributes the improved financial results to higher sales volumes, cost-saving measures from prior restructuring, and strong performance in the QLS and G-T segments. New orders increased 19% to $14,996,000.
Capital Allocation:
- Dividends: Declared and paid $0.04 per share ($170,829 total).
- Share Repurchases: Repurchased 71,800 shares for $235,146. Approximately 218,600 shares remain available for repurchase under existing authorization.
- Investments: Purchased $919,844 in securities available for sale.
Risks and Contingencies:
- Market Risk: Exposure to foreign currency exchange rates; declining demand in defense/aerospace sectors affecting the T&M segment.
- Competition: Intense competition in specialty printers, data acquisition, and neurophysiology industries.
- Restructuring: Ongoing utilization of severance accruals from prior fiscal year restructuring ($131,140 remaining balance).
Investor Verification Checklist
- Segment Sustainability: Verify if the 51% growth in the G-T segment and 14% growth in QLS are sustainable given the 28% decline in the T&M segment.
- Inventory Levels: Inventory increased to $9.09M; confirm that inventory turns (3.0x) remain healthy relative to sales velocity.
- Foreign Exchange Impact: Assess the sensitivity of future earnings to currency fluctuations, as international sales grew significantly but were partially aided by favorable exchange rates.
- Debt Obligations: Confirm the status of the minimal current debt maturities ($6,065) and any undisclosed long-term obligations.
- Restructuring Completion: Monitor the drawdown of the remaining $131,140 severance accrual to ensure no additional unexpected charges.